

TEVA PHARMACEUTICAL INDUSTRIES LTD

Filed by
NEW YORK STOCK EXCHANGE LLC

FORM 25-NSE

(Notification filed by National Security Exchange to report the removal from listing and registration of matured, redeemed or retired securities Initial Filing Amendments)

Filed 09/14/26

Telephone	972 (3) 914-8213
CIK	0000818686
Symbol	TEVA
SIC Code	2834 - Pharmaceutical Preparations
Industry	Pharmaceuticals
Sector	Healthcare
Fiscal Year	12/31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 25

**NOTIFICATION OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number 001-16174

Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD
Exchange: NEW YORK STOCK EXCHANGE LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address: 124 Dvora Hanevia St
Tel Aviv,

4951033

Telephone number: 972 (3) 914-8213

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

American Depositary Shares, each representing one Ordinary Share

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

☐ 17 CFR 240.12d2-2(a)(1)

☐ 17 CFR 240.12d2-2(a)(2)

☒ 17 CFR 240.12d2-2(a)(3)

☐ 17 CFR 240.12d2-2(a)(4)

☐ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

☐ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements for the Securities Exchange Act of 1934, NEW YORK STOCK EXCHANGE LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-09-14

Date

By

Victoria Paper

Name

Manager, Market
Watch

Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. [See](#) General Instructions.

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES

The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on September 25, 2026, pursuant to the provisions of Rule 12d2-2 (a).

[X] 17 CFR 240.12d2-2(a)(3) That on September 14, 2026 the instruments representing the securities comprising the entire class of this security came to evidence, by operation of law or otherwise, other securities in substitution therefore and represent no other right except, if such be the fact, the right to receive an immediate cash payment.

Effective September 14, 2026, Teva Pharmaceutical Industries Limited, completed its mandatory exchange of American Depositary Shares (ADS), each representing one Ordinary Share in connection with the termination of the ADS program. Each ADS was exchanged for one ordinary share.

This Form 25 is being filed solely in connection with the discontinuation of the trading on NYSE of the American Depositary Shares, each representing one Ordinary Share of Teva Pharmaceutical Industries Limited (CUSIP: 881624209) and does not affect the continued listing on NYSE of the Ordinary Shares of Teva Pharmaceutical Industries Limited (CUSIP: M8769Q102).

The Exchange also notifies the Securities and Exchange Commission that as a result of the above indicated conditions this security was suspended from trading on September 14, 2026.